Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin

Basit Öğe Kaydı
dc.authoridAcet, Ahmet/0000-0003-1131-1878
dc.authoridPolat, Seyhan/0000-0002-8766-9094
dc.authoridParlakpınar, Hakan/0000-0001-9497-3468
dc.authoridParlakpinar, Hakan/0000-0001-9497-3468
dc.authorwosidErtan, Asli/AAE-6201-2021
dc.authorwosidAcet, Ahmet/AAB-3273-2021
dc.authorwosidPolat, Seyhan/JLL-4491-2023
dc.authorwosidParlakpınar, Hakan/T-6517-2018
dc.authorwosidpolat, seyhan/ABG-8275-2020
dc.authorwosidParlakpinar, Hakan/V-6637-2019
dc.contributor.authorParlakpinar, Hakan
dc.contributor.authorPolat, Seyhan
dc.contributor.authorAcet, Haci Ahmet
dc.date.accessioned2024-08-04T20:48:57Z
dc.date.available2024-08-04T20:48:57Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractCoronavirus disease 2019 (COVID-19) is a life-threatening infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 pandemic causing morbidities and even deaths worldwide revealed that there is urgent need to find pharmacological agents or vaccines. Although there are a lot of agents under investigation, there is no approved agent for the prevention or treatment of the COVID-19 yet. Treatment of patients remains mainly supportive as well as compassionate use of the agents under investigation. It is well established that excessive inflammatory and immune response and oxidative injury play a critical role in the pathogenesis of COVID-19. In this review, we aimed to update knowledge about pathogenesis, clinical features, and pharmacological treatment of COVID-19 and review the potential beneficial effects of ancient antioxidant, anti-inflammatory, and immunomodulatory molecule melatonin for prevention and treatment of COVID-19.en_US
dc.identifier.doi10.1111/fcp.12589
dc.identifier.endpage75en_US
dc.identifier.issn0767-3981
dc.identifier.issn1472-8206
dc.identifier.issue1en_US
dc.identifier.pmid32657483en_US
dc.identifier.scopus2-s2.0-85091688536en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage62en_US
dc.identifier.urihttps://doi.org/10.1111/fcp.12589
dc.identifier.urihttps://hdl.handle.net/11616/99558
dc.identifier.volume35en_US
dc.identifier.wosWOS:000577581600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofFundamental & Clinical Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectmelatoninen_US
dc.subjectCOVID-19en_US
dc.subjectrenin-angiotensin systemen_US
dc.subjectantioxidanten_US
dc.subjectanti-inflammatoryen_US
dc.subjectimmunomodulatoryen_US
dc.titlePharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatoninen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu